Graft Versus Host Disease (GVHD)

Cyclosporin/Cyclophosphamide Is a Potential New SOC in GVHD Management

Original Publication Date
Article Source
External Web Content
Cyclophosphamide plus cyclosporin, a calcineurin inhibitor, significantly improved graft-vs-host disease (GVHD)–free relapse-free survival (RFS) compared with standard prophylaxis in patients with aggressive blood cancers who are undergoing stem cell transplant from a matched…

Leo Luznik, MD

Institution
Johns Hopkins University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Original Publication Date
Article Source
External Web Content
Key Points Treg-engineered donor graft prevents acute and chronic GVHD. Patients treated with Treg-engineered graft who develop GVHD respond to primary corticosteroid therapy at a high rate. Abstract Allogeneic hematopoietic cell transplantation is a curative therapy limited by…

The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT

Original Publication Date
Article Source
External Web Content
Abstract The role of ABO blood group system mismatch on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes is controversial since current publications of large datasets are lacking. We retrospectively analyzed 30,487 patients transplanted between 2010 and 2021…

Status Update Support is Growing to Restore Funding to CDMRP and BMFRP Research Programs

Original Publication Date
Article Source
Status Update
Thanks to the efforts of our AAMDSIF bone marrow failure community and coalition partners, a bipartisan group of 105 U.S. House and 29 Senate members urged their leaders to restore funding to the Congressionally Directed Medical Research Programs ( CDMRP) including the Bone…

Raymond J. Hohl, MD, PhD

Institution
The Pennsylvania State University School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Hohl began his career at the University of Iowa, College of Medicine in 1991, where he served as assistant professor in the department of internal medicine. He became an assistant professor in the department of pharmacology in 1993 and was promoted to associate professor of both internal medicine and pharmacology in 1997. Dr. Hohl became the director of the division of hematology, oncology and blood and marrow transplantation at the Roy J. and Lucille A. Carver College of Medicine, University of Iowa in 1995. In 1999, he became the associate director for clinical research for the Holden
Subscribe to Graft Versus Host Disease (GVHD)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.